This trial is evaluating whether Brentuximab Vedotin will improve 1 primary outcome, 7 secondary outcomes, and 2 other outcomes in patients with Refractory Hodgkin Lymphoma. Measurement will happen over the course of Up to 21 days.
This trial requires 29 total participants across 1 different treatment group
This trial involves a single treatment. Brentuximab Vedotin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"A causal relationship has been established between tobacco smoking and the development of lymphoma or the precursor lesion. For this, lymphoma is not a pure'smoker's disease'. More recent studies have questioned whether a causal relationship exists between Epstein-Barr virus and non-Hodgkin's lymphoma, but no causal role has been established yet." - Anonymous Online Contributor
"In recent years, chemotherapy and radiation treatment have become more standard practice. In older cases, surgery and/or radiation are still a valid treatment option. However, the trend in treating lymphoma is towards more individualized treatment, with the use of chemotherapy and/or radiation therapy in a more conservative manner, particularly for small B-cell lymphomas." - Anonymous Online Contributor
"A lymphoma is a cancer of the lymphatic system. In the UK more than 60 cases of non-IgM lymphoma a year are diagnosed, most commonly Burkitt's and non-Burkitt's Burkitt's-like lymphomas. The most common form of non-IgM lymphoma is mediastinal B-cell lymphomias. B-cells develop from the precursors of lymphoma. A lymphoma is diagnosed by analyzing the cells." - Anonymous Online Contributor
"More than three quarters of all patients with lymphoma got their disease in the United States. More than one-third of all patients had either aggressive or indolent B-cell NHL." - Anonymous Online Contributor
"Signs include the following: weight loss, bone pain, swollen lymph nodes, unexplained fatigue and malaise. Patients rarely complain of sore throat or swollen lymph nodes because these are common side effects of chemotherapy.\n" - Anonymous Online Contributor
"Despite the improvements in therapy and survival, approximately 50% of patients die from lymphoma in the United States each year. With better treatment, overall and median survival rates can be improved even further. It is impossible to assert that cure can be accomplished for every patient with lymphoma. What this article, the textbook reports, and the literature suggest must be recognized." - Anonymous Online Contributor
"This data suggested that a combination of viral infections, tobacco, drugs and environmental exposures may play a role in lymphoma. An association between smoking and certain subtypes of lymphoma is emerging, supporting the proposal that smoking exerts its effect by activating the immune system." - Anonymous Online Contributor
"Clinical trials are recommended for patients with both localized and advanced lymphoma in order to help ascertain treatment recommendations and prognoses in different lymphoma subtypes." - Anonymous Online Contributor
"Overall, BV significantly improved the quality of life of patients with relapsed or refractory bulky lymphoma and was well tolerated, albeit requiring frequent administration. The improvement in quality of life was most pronounced for physical well-being and mobility, with the improvements tending to be greatest in those who were symptomatic after the initiation of BV." - Anonymous Online Contributor
"Although fatal cases of lymphoma have been reported from the 18th century, the majority of fatalities have been reported for lymphoma occurring after the age of 40 due to multiple causes (especially congestive heart failure), but they are rare in younger patients. Most patients with malignant tumours of B-lymphocytic (or B-cell lymphocytic) origin do very well. Older patients with B-cell lymphomas often die of septic shock, or pneumonia and/or secondary tumours." - Anonymous Online Contributor
"It’s a complex disease and there have not been new drugs released in the cancer drug pipeline, but a plethora of research continues. As for non-Hodgkin’s lymphoma, research is ongoing. Research on how to prevent the disease continuing is still being done at the cellular level. There is also some research underway on how well we can control, but not cure the disease or eradicate it from the person. A lot of it is aimed at immunotherapy and immunotoxins." - Anonymous Online Contributor
"This novel therapy demonstrated durable responses with acceptable toxicity in this group of high-risk B-cell lymphoma. Brentuximab vedotin was safe and effective, and response data appear to be similar to our experience with other agents including rituximab." - Anonymous Online Contributor